



- (51) International Patent Classification:
C12Q 1/68 (2006.01)
- (21) International Application Number:
PCT/US2014/040003
- (22) International Filing Date:
29 May 2014 (29.05.2014)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/829,100 30 May 2013 (30.05.2013) US
- (71) Applicant: **GENOMIC HEALTH, INC.** [US/US]; 301 Penobscot Drive, Redwood City, California 94063 (US).
- (72) Inventors; and
- (71) Applicants : **SHAK, Steven** [US/US]; 301 Penobscot Drive, Redwood City, California 94063 (US). **WATSON, George Andrew** [US/US]; 301 Penobscot Drive, Redwood City, California 94063 (US). **CRAGER, Michael R.** [US/US]; 301 Penobscot Drive, Redwood City, California 94063 (US). **MADDALA, Tara** [US/US]; 301 Penobscot Drive, Redwood City, California 94063 (US). **LOPATIN, Margarita** [US/US]; 301 Penobscot Drive, Redwood City,

California 94063 (US). **GODDARD, Audrey** [CA/US]; 301 Penobscot Drive, Redwood City, California 94063 (US). **KNEZEVIC, Dejan** [US/US]; 301 Penobscot Drive, Redwood City, California 94063 (US). **SVEDMAN, Christer** [SE/US]; 301 Penobscot Drive, Redwood City, California 94063 (US).

(74) Agent: **HOFFMAN, David C.**; Genomic Health, Inc., 301 Penobscot Drive, Redwood City, California 94063 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,

[Continued on next page]

(54) Title: GENE EXPRESSION PROFILE ALGORITHM FOR CALCULATING A RECURRENCE SCORE FOR A PATIENT WITH KIDNEY CANCER

Figure 1

A. Predictiveness curves for patients with stage 1 ccRCC



(57) Abstract: The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.



UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*